People: Cytokinetics Inc (CYTK.W)

CYTK.W on CBOE When Trading NASDAQ Global Select Market

1.20USD
17 May 2013
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.20
Open
$1.17
Day's High
$1.20
Day's Low
$1.16
Volume
4,500
Avg. Vol
3,912
52-wk High
$1.45
52-wk Low
$0.63

Search Stocks

Summary

Name Age Since Current Position

L. Patrick Gage

 69 2010 Independent Chairman of the Board

Robert Blum

 48 2007 President, Chief Executive Officer, Director

Sharon Barbari

 57 2009 Chief Financial Officer, Executive Vice President - Finance

David Cragg

 56 2009 Senior Vice President - Human Resources

Andrew Wolff

 57 2004 Senior Vice President - Clinical Research and Development, Chief Medical Officer

B. Lynne Parshall

 2013 Director

Santo Costa

 66 2010 Independent Director

Stephen Dow

 57 2010 Independent Director

Denise Gilbert

 54 2008 Independent Director

John Henderson

 2009 Independent Director

Sandford Smith

 65 2012 Independent Director

Wendell Wierenga

 65 2011 Independent Director

Jodi Goldstein

 Primary IR Contact
» Insider Trading

Biographies

Name Description

L. Patrick Gage

 Dr. L. Patrick Gage serves as an Independent Chairman of the Board of Cytokinetics Inc. Dr. Gage has served as a member of Board of Directors since November 2009 and as Chairman of the Board of Directors since March 2010. Since July 2002, Dr. Gage has served as a consultant to the biopharmaceutical industry, including service as an advisor to venture capital firms. From 1998 to 2002, Dr. Gage was President of Wyeth Research and subsequently also Senior Vice President, Science and Technology. From 1989 to 1998, he held roles of increasing responsibility at Genetics Institute, Inc., first as head of Research and Development, then as Chief Operating Officer and eventually as President. From 1971 to 1989, Dr. Gage held various positions in research management with Hoffmann-La Roche Inc., most recently serving as Vice President responsible for U.S. drug discovery. Dr. Gage served on the Board of Directors of Neose Technologies from 2002 through 2009, and as the Chairman of its Board of Directors from 2006 through 2009. He served on PDL BioPharma, Inc.’s Board of Directors from 2003 through 2008, as the Chairman of its Board of Directors in 2007, and as its Interim Chief Executive Officer from 2007 through 2008. Dr. Gage served on the Board of Directors of Serono (now a subsidiary of Merck KGaA) from 2004 until 2007. Dr. Gage earned a bachelor’s degree in Physics from the Massachusetts Institute of Technology and a Ph.D. in Biophysics from the University of Chicago.

Robert Blum

 Mr. Robert I. Blum serves as President, Chief Executive Officer, Director of Cytokinetics Inc. He serves as a member of Board of Directors in January 2007. Previous to that appointment, Mr. Blum served as President from February 2006 to January 2007. He served as Executive Vice President, Corporate Development and Commercial Operations and Chief Business Officer from September 2004 to February 2006. From January 2004 to September 2004, he served as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From October 2001 to December 2003, he served as Senior Vice President, Corporate Development and Finance and Chief Financial Officer. From July 1998 to September 2001, Mr. Blum was Vice President, Business Development. Prior to joining in July 1998, he was Director, Marketing at COR Therapeutics, Inc., a biopharmaceutical company, since 1996. From 1991 to 1996, he was Director, Business Development at COR Therapeutics. Prior to that, Mr. Blum performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion Laboratories, Inc. and Syntex Corporation. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School.

Sharon Barbari

 Ms. Sharon A. Barbari serves as Chief Financial Officer, Executive Vice President - Finance of Cytokinetics Inc., since July 2009. She served as Senior Vice President of Finance and Chief Financial Officer from September 2004 through June 2009. From September 2002 to August 2004, she served as Chief Financial Officer and Senior Vice President of Finance and Administration of InterMune, Inc., a biopharmaceutical company. From January 1998 to June 2002, she served at Gilead Sciences, Inc., a biopharmaceutical company, most recently as Vice President and Chief Financial Officer. From 1996 to 1998, she served as Vice President, Strategic Planning at Foote, Cone & Belding Healthcare in San Francisco, an international advertising and marketing firm. From 1972 to 1995, she was employed by Syntex Corporation where she held various management positions in corporate finance, financial planning, marketing and commercial planning. Ms. Barbari received a B.S. in Accounting from San Jose State University.

David Cragg

 Mr. David W. Cragg serves as Senior Vice President - Human Resources of Cytokinetics Inc., since July 2009. He served as Vice President of Human Resources from February 2005 through June 2009. From October 2000 until January 2005, Mr. Cragg managed his own human resources consulting practice. From March 2000 until its acquisition in September 2000 by Yahoo!, Inc., he was Vice President, Human Resources for eGroups Inc., an Internet email management company. Prior to October 2000, Mr. Cragg was a Principal Human Resources Consultant at Genentech, Inc., a biotechnology company. Mr. Cragg received a B.A. in Industrial Psychology from the University of California, Santa Cruz.

Andrew Wolff

 Mr. Andrew A. Wolff, M.D., F.A.C.C. serves as Senior Vice President of Clinical Research and Development and Chief Medical Officer Cytokinetics Inc., since September 2004. From September 1994 until September 2004, Dr. Wolff held various positions of increasing responsibility at CV Therapeutics, a biopharmaceutical company, most recently as Senior Vice President and Chief Medical Officer. From 1988 until 1994, he served in various drug development positions of increasing responsibility in both the United States and the United Kingdom for Syntex Corporation, most recently as the Executive Director of Medical Research and New Molecules Clinical Programs Leader. Since 1986, Dr. Wolff has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently an Associate Clinical Professor, and is an Attending Cardiologist in the Coronary Care Unit at the San Francisco Veterans Administration Medical Center. Dr. Wolff received a B.A. in Chemistry and Biology from the University of Dayton and an M.D. from Washington University Medical School.

B. Lynne Parshall

 Ms. B. Lynne Parshal , Esq., is appointed as the Director of Cytokinetics, Incorporated. She joins the Cytokinetics Board of Directors with over 21 years of legal, financial, manufacturing, general management and corporate development experience in the biopharmaceutical industry. Ms. Parshall is currently a member of the Board of Directors and the Chief Operating Officer of Isis Pharmaceuticals, Inc., a public biopharmaceutical company focused on antisense drug discovery and development. Prior to joining Isis Pharmaceuticals, Ms. Parshall was a partner with the firm of Cooley Godward LLP, where she represented health care companies in a general practice specializing in corporate partnering and other technology-based transactions. Ms. Parshall currently serves on the Board of Regulus Therapeutics Inc., a public biopharmaceutical company co-founded by Isis. Ms. Parshall is a member of the American, California and San Diego bar associations. Ms. Parshall received her J.D. from Stanford Law School and her B.A. from Harvard University.

Santo Costa

 Mr. Santo J. Costa serves as an Independent Director of Cytokinetics Inc., since November 2010. Since 2007, Mr. Costa has served as Of Counsel to the law firm of Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P. of Raleigh, North Carolina, specializing in corporate law for healthcare companies. From 1994 to 2002, he held various positions at Quintiles Transnational Corporation, most recently as Vice Chairman and before that as President and Chief Operating Officer. Prior to joining Quintiles, Mr. Costa spent 23 years in the pharmaceutical industry, most recently as General Counsel and Senior Vice President, Administration with Glaxo Inc. Prior to joining Glaxo, he served as U.S. Area Counsel with Merrell Dow Pharmaceuticals and as Food & Drug Counsel with Norwich Eaton Pharmaceuticals. Mr. Costa has served as Chairman of LaboPharm, Inc. since 2006 and on the Board of Directors of Biovest Corp. I since 2010. He served as Chairman of NeuroMedix Inc. from 2005 to 2007 and served as a director of CV Therapeutics from 2001 to 2009, a director of OSI Pharmaceuticals from 2006 to 2010 and a director of NPS Pharmaceuticals from 1995 to 2007, as well as serving as a director at other private companies. Mr. Costa is an Adjunct Professor in the clinical research program at the Campbell University School of Pharmacy. Mr. Costa earned both a B.S. in Pharmacy and a J.D. from St. John’s University.

Stephen Dow

 Mr. Stephen M. Dow is no longer Independent Director of Cytokinetics Inc., effective May 22, 2013. He served as Lead Outside Director of the Board of Directors from February 2009 through March 2010. Mr. Dow has been a General Partner with Sevin Rosen Funds, a venture capital firm, since 1983. Since 1989, Mr. Dow has served on the Board of Directors of Citrix Systems Inc., an enterprise software company. He has served as the chief executive officer of two privately held software companies and served on the board of directors of numerous privately held companies in a variety of industries during his tenure at Sevin Rosen Funds. Mr. Dow received a B.A. in Economics and an M.B.A. from Stanford University.

Denise Gilbert

 Ms. Denise M. Gilbert, Ph.D., serves as an Independent Director of the Cytokinetics Inc., since May 2008. From 2001 to 2002, she served as Chief Executive Officer of Entigen Corporation, a private life science information technology company. From 1995 to 1999, Dr. Gilbert served as Chief Financial Officer and Executive Vice President of Incyte Pharmaceuticals (now Incyte Corporation). From 1993 to 1995, Dr. Gilbert was Chief Financial Officer and Executive Vice President of Affymax Inc. From 1986 through 1993, Dr. Gilbert was a Managing Director and senior biotechnology analyst at Smith Barney Harris & Upham and Vice President and biotechnology analyst at Montgomery Securities. Dr. Gilbert has served on the Board of Directors of Dynavax Technologies Corporation, a biopharmaceutical company, since 2004, and has served on the board of directors of a privately held biotechnology company since 2006. She served on the Board of Directors of Connetics Corporation, a pharmaceutical company, from 2003 to 2007. Dr. Gilbert holds a B.S. from Cornell University and a Ph.D. in Cell and Developmental Biology from Harvard University.

John Henderson

 Dr. John T. Henderson serves as an Independent Director of Cytokinetics Inc., since February 2009.Since December 2000, Dr. Henderson has served as a consultant to the pharmaceutical industry as president of Futurepharm LLC. Until his retirement in December 2000, Dr. Henderson was with Pfizer Inc. for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held Vice Presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for Pfizer’s Europe, U.S. and International Pharmaceuticals groups. Dr. Henderson has served on the Board of Directors of Myriad Genetics, Inc., a healthcare diagnostics company, since 2004, and served as the Chairman of Myriad’s Board of Directors since April 2005. He has served on the Board of Directors of Myrexis, Inc. (formerly Myriad Pharmaceuticals, Inc.) since its spin-off from Myriad Genetics, Inc. in June 2009. He also serves as the chairman of the Board of Directors of a privately held pharmaceutical research and development company. Dr. Henderson earned his bachelor’s of science and medical degrees from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.) and the Faculty of Pharmaceutics Medicine.

Sandford Smith

 Mr. Sandford D. Smith serves as an Independent Director of Cytokinetics Inc., since March 5, 2012. From 1996 to 2011, Mr. Smith held various positions at Sanofi-Genzyme (formerly Genzyme Corporation), most recently the integration of Genzyme’s international business into Sanofi’s global organization. Prior to that, he served as Executive Vice President of Genzyme Corporation, a biotechnology company, and President of Genzyme International. From 1986 to 1996, Mr. Smith was President, Chief Executive Officer and a member of the Board of Directors of RepliGen Corporation, a biotechnology company. From 1977 to 1985, Mr. Smith held various positions at Bristol-Myers Squibb, most recently serving as Vice President of Business Development and Strategic Planning for the Pharmaceutical and Nutritional Division. Mr. Smith has served on the Board of Directors of Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, since January 2012. He served on the Board of Directors of NVenta Biopharmaceuticals Corporation from 2007 to 2009, and on the Board of Directors at Ariad Pharmaceuticals, Inc., from 1991 to 2008, most recently as Vice Chairman and Lead Independent Director. Mr. Smith earned a bachelor’s degree from the University of Denver.

Wendell Wierenga

 Dr. Wendell Wierenga, Ph.D., serves as an Independent Director of Cytokinetics Inc., since February 9, 2011. Since June 2011, Dr. Wierenga has served as Executive Vice President, Research and Development, at Santarus, Inc., a specialty biopharmaceutical company. From 2006 to 2011, he served as Executive Vice President, Research and Development, at Ambit Biosciences Corporation. From 2003 to 2006, he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. (now part of Takeda Pharmaceutical Company). From 1990 to 2000, he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.) Prior to that, Dr. Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research. Dr. Wierenga has served on the Board of Directors of XenoPort, Inc., a biopharmaceutical company, since 2001 and on the Board of Directors of Onyx Pharmaceutics, Inc. since 1996. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University.

Jodi Goldstein

Basic Compensation

Name Fiscal Year Total

L. Patrick Gage

 --

Robert Blum

 1,458,200

Sharon Barbari

 820,687

David Cragg

 520,818

Andrew Wolff

 789,170

B. Lynne Parshall

 --

Santo Costa

 --

Stephen Dow

 --

Denise Gilbert

 --

John Henderson

 --

Sandford Smith

 --

Wendell Wierenga

 --

Jodi Goldstein

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

L. Patrick Gage

 0 0

Robert Blum

 453,925 2,132,955

Sharon Barbari

 128,500 60

David Cragg

 0 0

Andrew Wolff

 122,500 0

B. Lynne Parshall

 0 0

Santo Costa

 0 0

Stephen Dow

 0 0

Denise Gilbert

 0 0

John Henderson

 0 0

Sandford Smith

 0 0

Wendell Wierenga

 0 0

Jodi Goldstein

 0 0

Insider Trading

Name Shares Traded Price

BLUM ROBERT I

 110,895 $0.00

DOW STEPHEN M

 1,742,950 $0.61

SURREY-BARBARI SHARON A

 36,631 $0.76

BLUM ROBERT I

 175,000 $0.00

SURREY-BARBARI SHARON A

 100,000 $0.00

MALIK FADY IBRAHAM

 87,500 $0.00

CRAGG DAVID W

 22,894 $0.76

MALIK FADY IBRAHAM

 32,052 $0.76

CRAGG DAVID W

 62,500 $0.00

WOLFF ANDREW A

 32,052 $0.76

WOLFF ANDREW A

 87,500 $0.00

BLUM ROBERT I

 64,105 $0.76
» Full list on Insider Trading
Search Stocks